Caliway Biopharmaceuticals Co. L
6919
株式のランク
#4346
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated... Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phase 2 clinical trials, targeting non-surgical fat reduction, Dercum's disease, and cellulite. Beyond this, the firm is also progressing CBA-539 through preclinical exploration for potential applications in central obesity, hyperpigmentation, and skin aging. The company's offerings also extend to dietary supplements. Established in 2012, Caliway Biopharmaceuticals operates from its headquarters in New Taipei City, Taiwan.
株価
$2.29
時価総額
$3.56B
変化（1日）
-2.50%
変化（1年）
-57.22%
国
TW
取引 Caliway Biopharmaceuticals Co. L (6919)
カテゴリー
Healthcare
Caliway Biopharmaceuticals Co. L（6919）のEPS
2026 時点のEPS TTM: 0
Caliway Biopharmaceuticals Co. Lの最新の財務報告と株価によると、同社の現在のEPS（TTM）は0です。2026年末には、EPSは0で、2026年のEPS0と同等でした。
Caliway Biopharmaceuticals Co. LのEPS履歴（2026から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 提供された日付のデータは十分ではありません。 | ||
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| $27.74 | - |
NL
|
|
| - | - |
CH
|
